Going Concern Warning Issued Amidst Significant Losses and Clinical Trial Setback; Company Raises Capital with Substantial Dilution
COCP sits 15% above its 52-week low of $0.859.
Summary
Cocrystal Pharma issued a going concern warning in its 10-K, reporting substantial losses and a critical cash position, alongside a major setback in its Influenza A clinical program and significant dilutive capital raises.
Key Events · Financing and Capital Events · COCP
-
Substantial Doubt About Going Concern
Management and auditors have expressed substantial doubt about the company's ability to continue operations beyond the next 12 months, citing a net loss of $8.8 million and $8.2 million in cash used in operating activities for 2025, with an unrestricted cash balance of $7.0 million and working capital of $5.9 million as of December 31, 2025.
-
Significant Accumulated Deficit
The company reported an accumulated deficit of $342.2 million as of December 31, 2025, highlighting a history of losses and the need for continuous capital raises.
-
Influenza A Program Setback and CRO Dispute
A Phase 2a clinical study for the CC-42344 Influenza A candidate failed to yield scientifically viable efficacy results due to unexpectedly low infection rates. The company is in a dispute with the CRO, seeking a $6.3 million refund or a redo of the study, while the CRO is seeking an additional $0.6 million.
-
Dilutive Capital Raises in 2025
The company raised approximately $7.6 million in net proceeds during 2025 through a registered direct offering (2.76 million shares at $1.70/share with 5.53 million warrants) and an insider private placement (743,024 units at $1.39/unit, including warrants for 1.48 million shares), leading to significant shareholder dilution.
Analysis · COCP · Life Sciences
Cocrystal Pharma's 10-K filing reveals a critical financial situation, with management and auditors expressing substantial doubt about the company's ability to continue as a going concern. The company reported a net loss of $8.8 million and used $8.2 million in operating cash in 2025, with an accumulated deficit of $342.2 million. While the company successfully raised approximately $7.6 million through a registered direct offering and an insider private placement in late 2025, these capital infusions come with significant dilution and are a response to its precarious financial state. A major setback in the Influenza A program, where a Phase 2a study failed to yield viable efficacy data and led to a $6.3 million dispute with the CRO, further exacerbates operational and financial risks. Investors should be aware of the severe liquidity challenges and the high potential for further dilution.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 42% of the 479 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COCP was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $0.86 to $2.67. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.